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Abstract
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Whilst the chaperone activity of sHsps against amorphously aggregating proteins has been well studied,
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on the interaction of alpha B-crystallin and other sHsps with fibril-forming proteins is summarized. In
particular, the ability of sHsps to prevent fibril formation, their mechanisms of action and the possible in
vivo consequences of such associations are discussed. Finally, the fibril-forming propensity of the
crystallin proteins and its implications for cataract formation are described along with the potential use of
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Summary
Improper protein folding (misfolding) can lead to the formation of disordered (amorphous) or
ordered (amyloid fibril) aggregates. The major lens protein, α-crystallin, is a member of the small
heat-shock protein (sHsp) family of intracellular molecular chaperone proteins that prevent
protein aggregation. Whilst the chaperone activity of sHsps against amorphously aggregating
proteins has been well studied, its action against fibril-forming proteins has received less
attention despite the presence of sHsps in deposits found in fibril-associated diseases (e.g.
Alzheimer’s and Parkinson’s). In this review, the literature on the interaction of αB-crystallin and
other sHsps with fibril-forming proteins is summarized. In particular, the ability of sHsps to
prevent fibril formation, their mechanisms of action and the possible in vivo consequences of
such associations are discussed. Finally, the fibril-forming propensity of the crystallin proteins
and its implications for cataract formation are described along with the potential use of fibrillar
crystallin proteins as bionanomaterials.
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1. Introduction
Vision is arguably the most important of the senses. Crucial to vision is the ability of the eye lens
to focus light on to the retina. Proper lens transparency is highly dependent on the well-ordered
arrangement of the crystallin proteins, which are present in high concentration and make up
almost the entire composition of the lens. Disruption of crystallin protein arrangement, for
example as a result of protein aggregation and precipitation, leads to impairment of lens light
refraction, potentially cataract formation and, ultimately, loss of sight.
The nature of the aggregates that are formed by crystallin proteins during cataract formation is a
matter of debate, i.e. whether the aggregates are amorphous (unstructured) or highly ordered
(amyloid fibril) in form, or a combination of both. So too is the mechanism of crystallin protein
aggregation. There is no efficacious drug for cataract and current treatment involves removal of
the lens and its replacement with a plastic one. Clearly, determining the fundamental aspects of
the processes by which crystallin proteins aggregate will have important consequences for
understanding cataract and the development of possible therapeutics.
The major lens protein, α-crystallin, is a member of the small heat-shock protein (sHsp) family of
intracellular molecular chaperone proteins which interact with partially folded proteins to prevent
their mutual association and possible precipitation [1-3]. As a result of this ability, in addition to
its structural role in the lens, α-crystallin acts in a chaperone manner to prevent aggregation of
the crystallin proteins (including itself). α-Crystallin is composed of two, closely related
subunits, αA and αB, and is not lens specific. Apart from the lens, the αB subunit is expressed
extensively in many other tissues, including the brain, lung, and cardiac and skeletal muscle [4]
where it functions in a chaperone manner by interacting with a broad range of partially folded
target proteins. Thus, in vitro, αB-crystallin (and αA-crystallin) suppress the aggregation and
precipitation of a wide range of target proteins that precipitate amorphously or in a fibrillar form.
The interaction of αB-crystallin with the latter type of aggregating target proteins is of interest
because of the presence of amyloid fibrils in the proteinaceous deposits associated with many
diseases including Alzheimer’s and Parkinson’s and type II diabetes.
The interaction of α-crystallin with amorphously aggregating target proteins has been well
described and reviewed (e.g. [3, 5-7]), although specific details of the mechanism by which αcrystallin (and the sHsps, in general) accomplishes its chaperone action have not been elucidated.
In this review, we summarize the literature on the interaction of αB-crystallin and other sHsps
with target proteins that are aggregating to form amyloid fibrils and the possible in vivo
consequences of such associations. In addition, we describe our recent work investigating the
fibril-forming propensity of α-crystallin and the other crystallin proteins. The implications for
cataract formation are discussed along with the possible applications of crystallin amyloid species
in the emerging field of bionanomaterials.
2. Background to the crystallin proteins
Crystallins and the eye lens
The mammalian lens is a unique organ – it is avascular, it continues to grow throughout the life
of an individual and its lens fibre cells have little metabolic activity and are composed almost
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entirely of crystallin proteins which are not turned over [5, 8]. As a result, crystallin proteins at
the centre (nucleus) of the lens are as old as the individual itself. They are durable proteins, but,
due to the destabilizing influences with age of a combination of extensive post-translational
modification (for example truncation, phosphorylation, oxidation, deamidation and
racemization), as well as changes in cellular conditions, they eventually aggregate and precipitate
out of solution. This ultimately leads to the development of cataract [9] and, since the oldest
crystallin proteins are in the nucleus, age-related cataract initially occurs in the centre of the lens.
In addition to the α-crystallin subunits, the mammalian lens contains β and γ-crystallins [8]. Each
of these classes is comprised of a variety of closely sequence-related proteins (Table 1). For
example, the γ-crystallins encompass seven subunits, A, B, C, D, E, F and S of mass ~21 kDa
[10]. The β-crystallins encompass four acidic (A) and three basic (B) subunits of mass ~22-28
kDa of which the most populous is βB2. The β and γ-crystallins are homologous β-sheet proteins.
At a primary sequence level, the major difference between the β and γ-crystallins is the presence
of flexible terminal extensions in the former; the acidic β-crystallin subunits have an N-terminal
extension while the basic β-crystallin subunits have N- and C-terminal extensions [11, 12]. X-ray
crystal structures are available for representative subunits of both protein classes [10]. They share
the same secondary structure comprising two domains each of two Greek Key β-sheet motifs, i.e.
a total of 16 β-strands. However, due to the different arrangement of the connecting peptides (in
the γ-crystallins, the connecting peptide is bent and in β-crystallins, it is extended), the γcrystallins are monomers whereas the β-crystallins exist as a range of oligomers comprising
dimers through to octomers (Fig. 1A). Excellent review articles are available on structural aspects
of the β- and γ-crystallins (e.g. [10, 12, 13]).
The two subunits of mammalian α-crystallins, αA and αB, share over 50% sequence similarity
and each have a subunit mass of ~20 kDa [14-17]. In the human lens, they are present in a ratio
of approximately 3:1 αA: αB with the ratio varying with age. The two subunits co-exist as large,
heterogeneous complexes of mass range of approximately 160 to 1000 kDa. No crystal structure
is available for any α-crystallin subunit, although recently structures have become available for
three non-mammalian, but well-ordered, sHsp oligomers [18-21]. The building block for these
sHsps is a dimer and thus, due to the sequence similarity between sHsp members, the α-crystallin
oligomer is also probably built up from dimeric subunits. α-Crystallin subunits have three
structural regions (Fig. 1B and 1C), of which the C-terminal domain (of around 90 amino acids in
length) is relatively well conserved across all sHsps and adopts an immunoglobulin-like β-sheet
fold [19, 22]. The C-terminal domain in sHsps is sometimes known as the α-crystallin domain
and most likely comprises one or more of the peptide-binding regions that are involved in
interacting and binding to target proteins during chaperone action. Flanking the C-terminal
domain are two regions of less sequence similarity: (i) the N-terminal domain which is important
in subunit-subunit interactions, i.e. the quaternary arrangement of the protein, and possibly,
chaperone interaction [23, 24] and (ii) the C-terminal extension which contains a region of
polarity, great mobility and no defined structure at the extreme C-terminus. This flexible region
of 10 to 12 amino acids is important in solubilizing the protein and the complexes it makes with
target proteins during chaperone action [2, 3, 25]. In addition to flexibility at the C-terminus,
there are other regions of mobility in the protein, features which may facilitate their interaction
with target proteins during chaperone action. In general, significant conformational flexibility
and structural disorder are characteristics of molecular chaperone proteins [26]. Both subunits of
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α-crystallin, along with all other sHsps that have been studied, are highly dynamic oligomeric
species in which the subunits undergo constant exchange at physiological temperatures, with the
rate of exchange increasing at higher temperature [27].
Protein aggregation pathways and the chaperone action of α-crystallin against amorphously
aggregating target proteins
The description of the chaperone action of α-crystallin by Horwitz [1], Bhat’s observation that
αB-crystallin was not lens-specific and is found in many other tissues [28], and extensive
experimental evidence that αB-crystallin (and other sHsps) are associated with a wide range of
diseases (see below), have led to greatly enhanced research interest in the protein. Over the past
ten years, there have been significant advances in understanding the chaperone action of αcrystallin (and other sHsps) in mitigating target protein unfolding and aggregation. Review
articles are available which have extensive discussion of the chaperone action of α-crystallin
towards amorphously aggregating target proteins [3, 5, 6, 19, 25, 29-31], so this topic will not be
presented in detail here. However, so that the chaperone action of α-crystallin can be discussed
and understood with relevance to this review, the pathways and mechanisms of protein
aggregation must be elaborated upon.
Immediately after synthesis on the ribosome, a protein is in an unfolded state (U) (Fig. 2). It
folds into its native, functional form (N) via the folding/unfolding pathway that involves a series
of partially folded intermediate states (I1, I2, I3,…) that have varying degrees of structure, for
example molten globule states that have elements of secondary structure but little or no tertiary
structure. The intermediate states have their hydrophobic core exposed to solution and are
therefore inherently unstable and prone to incorrect folding (misfolding) and mutual association
(aggregation). To avoid possible interactions between these intermediates, most proteins fold
rapidly (in the order of micro to milliseconds), many without the need for assistance from
molecular chaperone proteins that facilitate and encourage correct protein folding, e.g. Hsp70 and
Hsp60 [32].
However, if the protein lingers for too long in this partially folded state(s) it may enter the slower
off-folding pathways that lead to aggregation and possibly precipitation. This process may also
occur if the native protein is destabilized by stress conditions, for example by elevated
temperature, which disrupts hydrogen bonding and hydrophobic interactions between some side
chains and results in its partial unfolding leading to the intermediately folded species entering one
of the off-folding pathways. There are two off-folding pathways that a protein may enter:
amorphous and amyloid fibril [33] (see Fig. 2). As the name implies, the amorphous aggregation
off-folding pathway gives rise to disordered aggregates that contain the partially folded
intermediates in a relatively extended conformation. Via a nucleation-dependent mechanism and
when a certain size of the aggregate (a nucleus) is reached, rapid sequestration of other
intermediates occurs, leading to a randomly arranged aggregate that exposes significant
hydrophobicity to solution, is unstable and therefore irreversibly precipitates. The amyloid fibril
pathway also arises from the association of intermediate states via a nucleation-dependent
mechanism but, in this case, the aggregates are highly ordered in structure. The aggregation
process involves the formation of a prefibrillar nucleus that may be a dimer, trimer or a larger
oligomer. Eventually, as with amorphous aggregation, the aggregates precipitate out of solution.
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The factors which govern whether a protein enters the amorphous or amyloid fibril off-folding
pathway are not entirely clear. However, the rate at which the aggregation occurs is important,
with more rapid aggregation favouring the amorphous pathway whereas the fibril pathway is
characterized by a slower rate of aggregation which enables the formation of well-structured
amyloid fibrils. Other factors which impact on the type of aggregates are the nature of the
intermediates from which they are formed and the amino acid sequence of the protein concerned.
With regards to the latter, certain amino acid sequences are highly amyloidogenic and there are
algorithms available to predict such regions based on amino acid sequence alone [34, 35].
It is clear from a variety of studies that α-crystallin interacts with amorphously aggregating,
intermediately folded target proteins early on their off-folding pathway, i.e. when the former are
in a monomeric, destabilized state [36, 37]. In doing so, α-crystallin binds to the target protein to
form a stable complex of large mass. α-Crystallin exhibits high stoichiometry (i.e. capacity) in
binding to target proteins with up to one target protein being bound per subunit of α-crystallin.
Mechanisms have been proposed for the chaperone interaction of α-crystallin (and sHsps) with
target proteins in which the dissociated, dimeric form of α-crystallin is more chaperone active
than the aggregated (oligomeric) species (Fig. 3), implying that subunit exchange involving the
dimeric species is important in chaperone action [3, 27, 29, 38]. However, other studies have
shown that the chaperone activity and rate of subunit exchange are not correlated (e.g. [39, 40])
and therefore the involvement of subunit exchange in the mechanism of chaperone action of αcrystallin is somewhat controversial.
α-Crystallin and all other sHsps are ATP-independent molecular chaperones. Their expression is
turned on under conditions of cellular stress (e.g. elevated temperature) when ATP levels are low.
Under these conditions, sHsps interact and complex to the long-lived, partially folded,
destabilized target proteins but have no ability to refold them (Fig. 3) [41]. The interaction
between the two proteins is most likely facilitated by the dynamic nature of the α-crystallin
oligomer (i.e. subunit exchange and conformational flexibility and malleability) along with a
similar process being undertaken by the target protein during its unfolding and mutual
association. The two proteins thereby become co-incorporated into a high molecular weight
(HMW) chaperone-target protein complex. In the process of interaction between the two proteins,
cryo electron microscopy data suggest that the target protein coats the outside of the α-crystallin
oligomer [7]. When cellular conditions return to normal, the native state of the target protein can
be recovered via the action of other molecular chaperones, e.g. Hsp70, coupled with ATP
hydrolysis (Fig. 3) [29]. Thus, it is probable that, in vivo, these two chaperones, α-crystallin and
Hsp70, function in a synergistic manner.
Recent studies by Mchaourab and colleagues on the interaction of destabilized T4 lysozyme
mutants with sHsps have led to a proposed mechanism of sHsp chaperone action in which the
equilibrium between the folding and unfolding of the target protein (T4 lysozyme) is coupled to
the equilibrium between the dissociated (dimeric) and oligomeric states of α-crystallin [42-44].
α-Crystallin binds T4 lysozyme in two modes with high and low affinity. In this model, the
dimeric form of the sHsp is the activated state which recognizes and binds to the destabilized
target protein [44].
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In addition, the chaperone action of α-crystallin is modified by environmental conditions, for
example temperature and pH. With increasing temperature, both subunits of α-crystallin partially
unfold which is accompanied by an increase in exposed hydrophobicity to solution and enhanced
chaperone ability [45-48]. The increase in α-crystallin subunit exchange rate with elevated
temperature [27] may also contribute to this increase in chaperone ability.
sHsps and disease
There are ten sHsps in the human genome [49, 50]. After αA- and αB-crystallin, the most
populous sHsp is Hsp27 (Hsp25 in mouse). Other sHsps include Hsp20, HspB2 and HspB3.
They are found in varying levels in different organs, depending on the stage of development and
the level of stress present and are capable of forming mixed sHsp oligomers, i.e. ones that are
composed of two or more sHsps. Plants have a multitude of sHsps [19]. The specific functions of
these sHsps in various organisms are far from understood. What is most likely is that all sHsps
share the common trait of interacting with partially folded, destabilized states of target proteins.
They are involved in a wide variety of cellular tasks such as actin polymerization, regulating
cellular redox states and caspase protein inactivation (i.e. as negative regulators of apoptosis).
Of late, it has become apparent that many seemingly unrelated diseases, particularly those of
ageing, are characterized by the accumulation and precipitation of specific proteins. They are
categorized under the broad umbrella of protein misfolding or conformational diseases and
include Alzheimer’s, Parkinson’s, Creutzfeldt-Jakob and Huntington’s and, of course, cataract. In
each case, the deposits that are characteristic of the disease contain the predominance of one
protein, i.e. β amyloid peptide in Alzheimer’s, α-synuclein in Parkinson’s, prion protein in
Creutzfeldt-Jakob, huntingtin in Huntington’s and crystallin proteins in cataract. In the case of
the first four of these diseases, the deposits or plaques contain the proteins in an amyloid fibrillar
form. Associated with these deposits are a variety of other proteins, i.e. molecular chaperones
including sHsps, particularly αB-crystallin and Hsp27, which are presumably expressed by the
cell in response to the presence of the aggregating fibrillar species (see below). Furthermore,
sHsps are implicated in a variety of other diseases including cancers and multiple sclerosis [31,
51].
An amyloid fibril is a generic structure that is accessible to all proteins, under the appropriate
conditions [33]. It is comprised of a cross β-sheet structure in which the polypeptide chain is
arranged in β-sheets stacked perpendicular to the axis of the fibril forming a steric zipper [52-56].
Amyloid fibrils are composed of two to six protofibrils that plait together to form rope-like
structures of 5 to 10 nm in diameter and up to hundreds of nm in length. The structural features of
amyloid fibrils are highlighted in Figure 4. Fibrils are highly stable structures and are resistant to
proteases and denaturants which may account for the difficulty that cellular degradation
mechanisms have in removing them once they have formed.
The mechanism(s) by which amyloid fibrillar species cause disease are a matter of debate but
they may involve processes leading to the production of free radicals and/or the formation of
pore-like structures which permeabilise the cell membrane. Precursors to amyloid fibres,
particularly small oligomeric species, may be toxic, i.e. there is evidence, at least for some
proteins, that the fibrillar species is inert [33]. However, for other proteins the mature fibril can
also be toxic [57, 58] and, in fact, the cytotoxic species may vary depending on the fibril-forming
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protein. By way of a caveat to these discussions, it has recently been recognized that functional
amyloid fibrils exist in nature, i.e. not all amyloid fibrillar forms are detrimental to cells [59].
Obviously, to avoid toxic effects, the production of functional amyloid fibres has to be tightly
regulated.
In this review, the interaction of α-crystallin (and other sHsps) with fibril-forming proteins and
its possible implications, are major topics for discussion.
3. Association of sHsps with amyloid diseases.
The expression of some sHsps is dramatically up-regulated in response to pathological conditions
associated with fibril formation. For example, induction of sHsps has been reported in
Alexander's disease [60], Creutzfeldt–Jakob disease [61], Alzheimer's disease, [62, 63] and other
neurological conditions [64-69]. Moreover, sHsps have been found to co-localize with the protein
aggregates associated with a number of these protein misfolding diseases and/or are found at
significant levels in neurons that surround the deposits (see below for details). Together, these
data suggest that the cell perceives events leading to amyloid fibril formation as a stress and acts
accordingly by inducing expression of sHsps. It also implies an important role for sHsps in
amyloid diseases, indicating that they are the first line of defence for the cell in its attempt to
mitigate amyloid fibril formation by the particular disease-associated protein. In particular, their
localization to activated glia cells such as astrocytes [63, 70] implies an important role for sHsps
in these cells in neurodegenerative diseases. Despite the correlation between sHsp expression and
co-localization with amyloid fibril deposits in various protein conformational diseases, the
precise role of sHsps in interacting with the aggregating target protein and the subsequent effect
on its toxicity remains controversial and may differ for various target proteins.
An intriguing link between fibril formation and the ability of sHsps to prevent the toxicity
associated with this process has been found by studies showing that Hsp27 and αB-crystallin
increase the resistance of cultured cells [71-73] and mice [74, 75] to oxidative stress. In addition,
Hsp27 and αB-crystallin expression has been found to negatively correlate with levels of reactive
oxygen species and nitric oxide. This may be significant due to findings indicating that the
toxicity of prefibrillar amyloid species is due to the production of reactive oxygen species by the
aggregating target protein, which are generated as a consequence of the fibril-forming process
[76]. Therefore, sHsps may act both as amyloid inhibitors to stop fibril formation and also as
mediators of cell redox resistance.
sHsps and α-synuclein based diseases (synucleinopathies).
An example of the relationship of sHsps with diseases associated with amyloid fibrils is the
synucleinopathies, i.e. diseases that are characterized by fibrils formed by the protein α-synuclein
which subsequently forms intracellular fibrillar inclusions called Lewy bodies. The aggregation
of α-synuclein into these protein deposits is thought to play a central role in the pathogenesis of
synucleinopathies [77-79]. The synucleinopathies include both familial and sporadic Parkinson’s
disease in which α-synuclein is localized in Lewy neurites in addition to its deposition in Lewy
bodies. The immunoreactivity of α-synuclein in Lewy body deposits is also the characteristic
pathological hallmark of dementia with Lewy bodies (DLB) in which Lewy bodies can be found
throughout the brain [80]. In addition, multiple system atrophy is a neurodegenerative disease
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that is associated with filamentous protein aggregates primarily composed of α-synuclein that
occur as glial cytoplasmic inclusions (GCIs). sHsps are located in neuritic plaques and Lewy
bodies in brain tissue from Parkinson’s disease patients and related synucleinopathies [81, 82].
For example, several Hsps, including Hsp27 and αB-crystallin, co-localise with α-synuclein
Lewy body deposits of DLB and GCIs [68, 82]. A recent study found Hsp27 levels were 2.5-fold
higher in brains of patients with DLB compared to controls [69] and in a mouse model of
Parkinson’s disease, the levels of Hsp25 and αB-crystallin were also found to be significantly
higher than controls [83]. These results are suggestive of sHsps playing a role in the disease
process and a stress response being invoked by the aggregation of α-synuclein. In support of this,
cell-culture models of α-synuclein aggregation have shown that Hsp27 perturbs the aggregation
process, and in so doing so inhibits the associated toxicity [69, 84]. It appears that Hsp27 inhibits
the formation of toxic α-synuclein aggregates at an early time point in its aggregation.
sHsps and Alzheimer’s disease.
The main histological characteristic of Alzheimer’s disease is the deposition of amyloid-β (Aβ)
peptides in extracellular plaques in the central nervous system and the walls of cerebral blood
vessels, as well as intracellular tangles of the tau protein in surrounding neurons. The amyloid
plaques, besides containing fibrillar forms of the Aβ peptides, also contain several other proteins
including sHsps [62, 70]. In addition, these chaperones are also expressed in neurons that
surround these deposits [63, 70]. Quantitative reverse transcription-PCR has also been used to
demonstrate increased accumulation of αB-crystallin mRNA in select regions of post-mortem
Alzheimer’s disease brains [85] and increased levels of the protein have been reported in the
temporal and frontal cortex [62, 86]. In addition, Hsp27 is associated with neurofibrillay tangles
of hyperphosphorylated tau protein [87]. With regards to the localization of sHsps in senile
plaques associated with Alzheimer’s disease, whilst there have been reports of extracellular
sHsps [88], they are predominately regarded as intracellular proteins. Thus, their extracellular
deposition is most likely as a consequence of their release from surrounding cells due to the toxic
effects of the aggregation process.
In a series of elegant papers using transgenic Caenorhabditis elegans worms, the expression of
human Aβ(1-42) was found to lead to the induction of Hsp16 proteins (sHsps that are homologs
of αB-crystallin in vertebrates) [89]. Furthermore, the Hsp16 proteins co-localized and coimmunoprecipitated with Aβ(1-42) in this model [89] and increased expression of Hsp16 partially
suppressed the Aβ-mediated toxicity [90]. It was concluded that sHsps such as Hsp16 may act to
reduce Aβ toxicity by interacting directly with the Aβ peptide and altering its oligomerization
pathways, thereby reducing the formation of some toxic species [90].
sHsps and other diseases associated with amyloid fibrils.
The poly(Q)protein-based aggregation diseases, which include Huntington’s disease, result in
intranuclear and cytoplasmic inclusion bodies in which the expanded poly(Q) protein (e.g.
huntingtin in Huntington’s disease) is present in a fibrillar form. Cell culture models of cell death
due to poly(Q) protein-based aggregation have shown that whilst co-expression of Hsp27 reduces
cell death, this is not mediated through a reduction in the number of cells with aggregates [91] but
correlates with a decrease in free radical production. In a recent study, a mutant huntingtin
protein was expressed in the ocular lenses of transgenic mice leading to protein aggregation and
cataract formation [92]. Significantly, in mice lacking αB-crystallin, the onset and severity of
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aggregation was markedly accelerated [92]. sHsps have also been found to be highly expressed in
astrocytes in the brains of patients with Creutzfeldt–Jakob disease (in which the fibril forming
protein is the prion protein) [61] and the expression of Hsp25 and αB-crystallin is increased in
transgenic mouse models of familial amyotrophic lateral sclerosis [83].

4. In vitro studies on the effect of sHsps in preventing fibril formation and its associated toxicity
Whilst early studies on the chaperone activity of sHsps were primarily focused on amorphously
aggregating target proteins, over the past ten years the role of these chaperone proteins in
preventing ordered aggregation leading to amyloid fibril formation in vitro has also been well
established. The chaperone activity of sHsps against in vitro fibril formation by target proteins
has to date focused predominately on αB-crystallin, most likely due to its links with the fibrillar
deposits associated with protein misfolding diseases (see above). Also, the chaperone activity of
αB-crystallin can be easily compared with well-established data on its chaperone activity against
amorphously aggregating target proteins. Thus, studies have shown that αB-crystallin inhibits the
fibrillation of α-synuclein [48, 83, 93], β2-microglobulin [94] (Esposito, Carver, et al.,
unpublished results), κ-casein [95, 96], the ccβ-Trp peptide [95], apoC-II [97], and the prion
protein (Ecroyd, unpublished results). In doing so, αB-crystallin acts as a chaperone under a
range of solvent conditions, including at pH values as low as 2.5 against β2-microglobulin
fibrillation [94].
sHsps and the Aβ peptides
The Aβ peptides (i.e. Aβ(1-40) and Aβ(1-42)) have been the most widely studied fibril-forming
targets against which the activity of sHsps has been assessed. The most studied sHsp in this
context has been αB-crystallin. However, to date there is no consensus on the overall effect of
αB-crystallin on fibril formation by Aβ peptides and the effect of this chaperone on the toxicity
associated with the fibril forming process by Aβ. The variance in the reported results is no doubt
due to differences in the experimental methods used. Stege et al. [98] reported that a sample
containing a 1.0: 0.2 molar ratio of Aβ(1-40): αB-crystallin led to an increase in toxicity to
isolated rat neurons compared to Aβ(1-40) alone (all molar ratios are stated as per monomeric
unit of the sHsp). However, these toxicity experiments involved the proteins being applied
directly to cells in the culture medium (i.e. the peptide was not incubated previously in the
presence and absence of αB-crystallin to induce its aggregation) and the fibril-forming propensity
of the Aβ peptide in the culture medium used was not reported. Therefore, whether the measured
toxicity correlates with that involved in the aggregation of Aβ(1-40) is not clear. These authors
reported that when the aggregation of Aβ(1-40) was studied in phosphate buffer under
physiological conditions (i.e. 37°C and pH 7.4), the presence of αB-crystallin (at the same molar
ratio of Aβ(1-40): αB-crystallin, i.e. 1.0: 0.2) resulted in an increase in thioflavin T (ThT)
fluorescence. However, no fibrils were seen by electron microscopy and this led to the conclusion
that αB-crystallin induces and/or stabilizes a non-fibrillar, β-sheet rich Aβ(1-40) species
(protofibril) which is highly toxic to these neuronal cells [98]. An increase in the level of ThT
fluorescence of Aβ(1-40) incubated in the presence of αB-crystallin compared to Aβ(1-40)
incubated alone was also reported by Liang [99] using a 1.0: 0.5 molar ratio of Aβ(1-40): αBcrystallin. Using a fluorescence energy transfer approach, Liang concluded that a stable complex
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forms between the chaperone and Aβ peptide which promotes the aggregation of Aβ(1-40) and
hence leads to an increase in ThT fluorescence [99].
In contrast to these studies, Kudva et al. [100] reported that α-crystallin (made up of both αAand αB-crystallin subunits) had no effect on the initial rate of fibril formation by Aβ(1-42) when
used at a 1.0: 0.3 molar ratio of Aβ(1-42): α-crystallin. Wilhemus et al. [101] showed that αBcrystallin (at a 1.0: 1.0 molar ratio) completely inhibited the formation of fibrils by DAβ(1-40) (a
Dutch mutation of Aβ(1-40) where Glu22 is replaced by Gln which forms fibrils more rapidly
than the wild-type Aβ(1-40) peptide) and delayed the formation of fibrils by Aβ(1-42) (as
assessed by TEM). They also found that the toxicity of aggregated DAβ(1-40) and Aβ(1-42) to
human brain pericytes was completely abolished by co-incubation with αB-crystallin (at a 1.0:
0.2 molar ratio of DAβ(1-40): αB-crystallin and a 1.0: 0.02 molar ratio of Aβ(1-42): αBcrystallin). Raman et al. [94] have reported that the increase in ThT fluorescence associated with
fibril formation by the Aβ peptides is completely inhibited by a 1.0: 0.05 molar ratio of Aβ(140): αB-crystallin and a 1.0: 0.1 molar ratio of Aβ(1-42): αB-crystallin (αB-crystallin was also
found to be more effective at preventing the fibril formation of Aβ(1-40) than αA-crystallin).
These authors concluded that no stable complex forms between αB-crystallin and Aβ(1-40), but
instead αB-crystallin acts primarily by forming a complex with the fibril nucleus to prevent its
growth [94]. αA-Crystallin has also been shown to completely inhibit fibril formation by Aβ(140) at a 1.0: 0.2 molar ratio (Aβ(1-40): αA-crystallin) and when αA-crystallin was added
together with Aβ(1-40) to rat neuronal (PC12) cells (at the same molar concentration), it
suppressed the toxicity compared to when Aβ(1-40) was added on its own [102].
A number of other sHsps inhibit in vitro fibril formation by the Aβ peptides. For example, a
study by Wilhemus [101] using five different human sHsps (αB-crystallin, Hsp20, Hsp27, HspB2
and HspB3) reported that whilst αB-crystallin, Hsp20 and Hsp27 effectively inhibited fibril
formation by DAβ(1-40), they had no effect on Aβ(1-42) aggregation. However, this study
reported that these three sHsps (i.e. αB-crystallin, Hsp20 and Hsp27) were effective inhibitors of
the cerebrovascular toxicity associated with the aggregation of both forms of Aβ (indicating that
aggregation and toxicity are not correlated in the case of Aβ fibril formation) [101]. In support of
this, a separate study by Lee et al. [103] using sHsps from three different sources (Hsp20 from
the parasite Babesia bovis, Hsp 17.7 from carrot and Hsp27 from humans) found that, whilst
sHsps may prevent fibril formation (with Hsp20 from B. bovis being the most effective), this did
not correlate with a decrease in the toxicity of Aβ(1-40) aggregates to cultured cells. Similar
observations have been reported using the C. elegans model whereby chaperone suppression of
Aβ toxicity is independent of a reduction of toxic protein accumulation per se [90].
Due to the conflicting results of these studies, the ability of sHsps, and in particular αB-crystallin,
to prevent the aggregation of Aβ peptides remains to be definitively established. In addition, the
results highlight the need for an assessment (using standardized protocols) of both the effect of
the chaperone on preventing fibril formation and the toxicity associated with this process. The
finding that sHsps inhibit fibril formation, but increase the toxicity of the Aβ aggregation process
is intriguing and should also be studied using other target proteins that form fibrils. Moreover, the
generic nature of the toxic species formed during fibril formation is yet to be established and
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sHsps may help to determine if any structural differences exist between the toxic species from
various aggregating proteins.
The mechanism by which sHsps prevent amyloid fibril formation.
There appears to be mechanistic differences in the ability of sHsps to prevent amyloid fibril
formation compared to amorphous aggregation. This conclusion is based on studies which have
compared the chaperone activity of mutant and/or chimaeric forms of α-crystallin proteins, (i.e.
proteins in which the N-terminal domain of αB-crystallin has been fused with the C-terminal
domain of αA-crystallin and vice-versa) [94] against both amorphous and amyloid fibril forming
target proteins. For example, the chaperone activity of the R120G αB-crystallin mutant (which is
linked to desmin-related myopathy and early onset cataract) towards amorphously aggregating
target proteins is significantly reduced compared to the wild-type protein [104, 105], however, its
ability to prevent fibril formation by Aβ(1-40) is only slightly lower [94]. As well, although a
deletion mutant of αB-crystallin (in which residues 21-29 in the N-terminal region have been
deleted) exhibits several fold increase in chaperone activity towards amorphously aggregating
insulin and citrate synthase compared to wild-type αB-crystallin, it shows only a marginal
increase in ability over the wild-type protein to prevent fibril growth by Aβ(1-40) [94]. Similarly,
we found that a double mutation in the C-terminal hinge region of αB-crystallin (i.e.
I159A/I161A αB-crystallin) had no effect on its chaperone activity against amorphously
aggregating target proteins, but it significantly enhanced its ability to prevent fibril formation by
the model proteins κ-casein and ccβ-Trp [106]. Thus, whilst all sHsps share structural features,
such as a conserved α-crystallin domain, the differences between the proteins play an important
role in their interaction with target proteins. Whether these differences are manifested through
distinct target protein binding sites or binding modes remains to be determined. Interestingly, this
raises the possibility that mutant forms of sHsps may be designed as more effective inhibitors of
fibril formation compared to the wild-type protein and therefore may be an avenue for therapeutic
potential in the future [106]. In addition, the variation in chaperone activity of sHsps may provide
clues as to the different nature of the partially folded intermediate which are the precursor(s) to
disordered (amorphous) versus ordered (amyloid fibril) forms of aggregation.
The mechanism of action of sHsps in preventing fibril formation also appears to vary depending
on the nature of the target protein (see Fig. 4E). Studies such as those with apolipoprotein C-II
(apoC-II) have shown that, in preventing amyloid fibril formation, sHsps can act at very low substoichiometric ratios and do not form stable complexes with partially folded intermediates of the
aggregating target protein [97]. Instead the sHsp and target protein are proposed to form a
transient complex by which the sHsp stabilizes the aggregating protein before releasing it so that
it may refold back to its native state via the reversible on-folding pathway [97]. This is in contrast
to its mechanism of action in preventing fibril formation by α-synuclein and κ-casein, whereby
αB-crystallin forms a stable, soluble chaperone-target protein complex with the partially folded
intermediate of these target proteins (i.e. a ‘reservoir of intermediates’) [48, 93, 95]. This is
analogous to the mechanism of chaperone action used by sHsps against amorphously aggregating
proteins [2] (Fig. 3). In the case of α-synuclein, αB-crystallin redirects the protein from the
amyloid fibril forming pathway to the amorphous aggregation pathway (see Fig. 2) [93], a
process that would benefit the cell since these amorphous aggregates are non-toxic and more
easily degraded through the ubiquitin-proteasome system.
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In addition, αB-crystallin is able to halt the increase in ThT fluorescence associated with fibril
formation of α-synuclein after it has commenced, but has no capacity to disassemble preformed
fibrils [48]. αB-crystallin may elicit this effect by directly inhibiting the supply of partially folded
intermediate required for fibril elongation and stable nuclei formation, and/or by interacting with
the fibril itself to ‘cap’ it and prevent further growth. With regards to αB-crystallin acting directly
with the growing fibril following stable nuclei formation, this is the primary mode by which
Aβ(1-40) fibril formation is thought to be inhibited by αB-crystallin [94]. The differences in the
mechanism by which sHsps prevent fibril formation by various target proteins highlight their
capacity to influence both the nucleation and propagation processes. The primary mechanism by
which sHsps prevent a particular aggregating species from forming fibrils is likely to reflect the
relative importance of each phase of fibril formation for that amyloidogenic species.
We have previously shown that for the reduction-induced amorphous aggregation of target
proteins, there is a direct correlation between the mass of the target protein and the chaperone
ability of α-crystallin, i.e. as the mass of the target protein increases, a higher subunit molar ratio
of α-crystallin is required to completely suppress aggregation [107]. These results are
rationalised by consideration of steric factors in the chaperone ability of sHsps: the sHsps more
efficiently bind smaller target proteins on their surface than larger ones. Similarly, steric
hindrance is likely to contribute to differences in the chaperone ability of sHsps to inhibit fibrilformation. Furthermore, variation in oligomeric distribution for a particular sHsp (resulting from
factors such as mutations, a change in environmental conditions (e.g. heat) and/or posttranslational modifications) and between sHsps need to be considered when comparing relative
chaperone abilities of sHsps. A systematic study of the size of the fibril-forming target proteins
and the chaperone efficiency of sHsps is required to elucidate this relationship.
With respect to the ability of sHsps to inhibit amorphous aggregation, it is well established that
the kinetics of the aggregation process are a significant factor in the efficacy of sHsps to prevent
this process, i.e. sHsps are most effective against slowly-aggregating target proteins undergoing
amorphous aggregation [3, 36, 108]. This is because sHsps interact with intermediately folded
states of target proteins and thus the longer these states persist, the better the ability of sHsps to
interact with them. Similar logic can be applied to the comparative chaperone activity of sHsps
against fibril-forming proteins; however, there has not been a definitive study that has addressed
this area. On the basis of aggregation kinetics, one may conclude that sHsps would be better
suited to preventing fibril formation as compared to amorphous aggregation since the formation
of fibrils is typically a much slower process than amorphous aggregation. In support of this, the
limited work that has been done in this area suggests the longer the lag phase of fibril formation
(representing the time taken to form stable nuclei), the more effective the chaperone ability of
αB-crystallin. For example, αB-crystallin is more effective at inhibiting fibril formation by wildtype α-synuclein compared to A53Tα-synuclein which forms fibrils more rapidly (Ecroyd,
unpublished data). As well, when the rate of α-synuclein fibril formation is increased through the
addition of dextran (which acts as a molecular crowding agent), the effectiveness of αB-crystallin
as a chaperone decreases [93]. Moreover, we have previously suggested that the intermediate
formed during the fibril formation of κ-casein is very short lived compared to other proteins that
form fibrils through the typical nucleation-dependent mechanism [109]. This may, at least in part,
explain why comparatively high molar ratios of αB-crystallin are required to inhibit fibril
formation by κ-casein compared to other systems which have been studied (i.e. the molar ratio
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(target protein: αB-crystallin) to completely inhibit fibril formation for α-synuclein is 1.0: 0.25
[93], apoC-II is 1.0: 0.02 [97] and ccβ-Trp 1.0: 0.1 [95] compared to > 1.0: 1.0 for RCMκ-casein
[95]). These differences cannot be accounted for by simple comparison of the masses of the
target proteins, as discussed above (mass of α-synuclein is 14.5 kDa, RCMκ-casein is 19.0 kDa,
apoC-II is 8.8 kDa and ccβ-Trp is 2.2 kDa).
The effectiveness of αB-crystallin to act as a chaperone against a particular target protein is also
dependent on the various conformational states of the target protein’s intermediately folded
forms. This is because αB-crystallin has a differential mode of binding to target proteins that
reflects the latter’s free-energy of unfolding [43]: the more destabilised and unfolded substrates
have higher binding affinities to αB-crystallin [110]. Thus, each protein’s intermediate states may
vary in their structure, hydrophobicity and binding affinity for αB-crystallin leading to
differences in the relative effectiveness of αB-crystallin (and sHsps in general) to prevent fibril
formation by different target proteins.
The effect of post-translational modifications on the chaperone activity of sHsps against fibrilforming target proteins.
Both inside and outside the lens, the major post-translational modification described for αBcrystallin and Hsp25 is phosphorylation at three serine residues; in αB-crystallin these are S19,
S45 and S59 (S15, S78 and S82 in Hsp27) [111-114]. Various types of cellular stress, such as
heat, oxidation and increased intracellular calcium levels, stimulate the phosphorylation of sHsps
[111]. With regard to αB-crystallin, phosphorylation is mediated by at least two distinct mitogenactivated protein kinase enzymes, mitogen-activated protein kinases associated protein kinase2
(MAPKAPK2) and p42/p44 MAPK [111, 112, 115, 116] and, in the lens, phosphorylation
increases with age [117, 118]. However, even in the young lens, αB-crystallin is extensively
phosphorylated [113, 118]. All three sites of serine phosphorylation of Hsp27 are mediated by
MAPKAP kinases [119, 120]. In the brain, some of the αB-crystallin isolated from the
proteinaceous aggregates of patients with degenerative diseases [121], amyloid plaques and Lewy
bodies is phosphorylated [68]. However, it is not known whether there is a preference for the
phosphorylated forms of αB-crystallin to interact with the proteins associated with these deposits.
In fact, the role of phosphorylation of sHsps in their chaperone action is far from understood.
Introducing a negative charge into recombinant sHsps by replacing serine residues with
aspartate/glutamate mimics the natural phosphorylation state of the protein. This method has
been employed previously for αB-crystallin and led to similar effects as endogenously
phosphorylated αB-crystallin with regards to its oligomeric distribution [122], subcellular
localization [123] and cellular trafficking [124]. Biophysical characterisation studies of these
phosphomimics have shown that an increase in the number of sites that are phosphorylated
decreases the oligomerization of the protein [122] by disrupting the dimeric substructure within
the oligomer [125]. Studies using these phosphomimics against both amorphous and fibrilforming target proteins have shown that the effect of phosphorylation of αB-crystallin on its
chaperone activity is target protein specific [95]. The triple phosphomimic of αB-crystallin (i.e.
S19D, S45D, S59D αB-crystallin or 3DαB-crystallin) is a more effective chaperone in preventing
fibril formation by the natively unstructured target proteins κ-casein and α-synuclein compared
to the wild-type protein, but is less effective against the ccβ-Trp peptide which adopts a well-
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structured coiled-coil configuration in its native state prior to fibril formation [95, 126]. These
results emphasise the role of the conformational states of the target protein’s intermediately
folded forms on the relative chaperone ability of sHsps. Interestingly, 3DαB-crystallin forms
mixed oligomers with the wild-type protein and exhibits enhanced subunit exchange which may
be responsible for the increase in chaperone activity seen with some target proteins [126] rather
than a direct interaction of the phosphorylation site with the target protein..
Cell culture experiments investigating the role of phosphorylation of Hsp27 in protecting against
poly(Q)-aggregation and the associated cell toxicity of this aggregation process have shown that
unphosphorylated Hsp27, in its large oligomeric state, is more effective at protecting against
oxidative stress than the triple phosphomimic of Hsp27 [91]. These results were supported by
experiments involving the over-expression of MAPKAP kinase 2 and subsequent increased
phosphorylation of Hsp27, in which a decrease in the ability of the phosphorylated chaperone to
prevent poly(Q)-mediated aggregation and cell toxicity was observed [91]. Other than
phosphorylation, sHsps, and in particular the α-crystallins undergo a variety of other forms of
post-translational modifications including deamidation, oxidation, glycation and C-terminal
truncation. However, to date, the impact of these modifications on the chaperone ability of sHsps
to prevent amyloid fibril formation has not been investigated. This area of study is significant
since these post-translational modifications occur to a significant extent to the crystallin proteins
in the eye lens [12, 127-133]. There is increasing evidence that cataract may be an amyloid fibril
based disease (see below) and, as such, the impact of such modifications on the chaperone ability
of α-crystallin to prevent this process is highly relevant.
The region(s) of α-crystallin responsible for target protein binding and prevention of fibril
formation.
Hydrophobic sites in α-crystallin are thought to be responsible for its chaperone activity [45,
134-137] and hydrophobic peptides isolated from αA-crystallin (residues 70-88) [137] and αBcrystallin (residues 73-92 and 131-141) [24, 138] possess chaperone activity against amorphously
aggregating target proteins. The chaperone activity of these peptides results from their ability to
bind independently to target proteins [137]. These sequences are within the α-crystallin core
domain that is shared by all members of the sHsp family (Fig. 1B). The same peptide region in
αA-crystallin (i.e. residues 70-88) has also been shown to have anti-fibril forming activity against
Aβ peptides and inhibits the toxicity to rat pheochromocytoma cells (PC12) associated with
addition of Aβ to the culture medium [102, 139]. In addition, a peptide comprising residues 7385 of αB-crystallin has been shown to reduce the increase in ThT fluorescence associated with
fibril formation of four disease-related target proteins (Aβ(1-42), α-synuclein, β2-microglobulin
and transthyretin) by >50% when used at equimolar ratios [140]. Another αB-crystallin peptide
(residues 101-110) was also found to have high anti-fibril activity in this study [140]. Moreover,
the anti-fibril activity of these peptides was apparent under a range of solution conditions
(including a pH as low as 2.4 to induce fibril formation by β2-microglobulin). Systematic
truncation of these bioactive peptides led to the identification of four tetrapeptides that were
highly effective as inhibitors of fibril assembly of these target proteins, i.e. FSVN, NLDV,
HGKH and HEER [140].
Interestingly, the N-terminal region of the αA-crystallin 70-88 peptide (i.e. KFVIF; the
corresponding peptide region in αB-crystallin is RFSVN) has strong sequence similarity to a
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region of the fibril-forming core domain of Aβ(1-40), KLVFF [102, 141]. This region in Aβ(140) has recently been shown by NMR spectroscopy to be primarily involved in the interaction
between Aβ(1-40) and αB-crystallin [142]. Moreover, KLVFF of Aβ(1-40) facilitates the
elongation of fibrils formed from Aβ. Thus, it can be concluded that the isolated peptides from
αA-crystallin and αB-crystallin inhibit fibril formation by Aβ(1-40) by competing for this
binding site with monomeric forms of Aβ(1-40) during its aggregation [102, 140]. Significantly,
this same peptide region appears to mediate the chaperone activity of αB-crystallin against a
range of other disease-related, fibril-forming target proteins, including α-synuclein and β2microglobulin [138, 140]. At present, the development of therapeutics for Alzheimer’s disease is
largely focused on identifying inhibitors of fibril formation by Aβ peptides with some molecules
that exhibit high inhibitory activity having progressed to stage III clinical trials [143-145]. The
target protein specificity of these molecules (i.e. to Aβ peptides only) precludes their use as
therapeutic agents for other fibril-related diseases, but their success highlights the potential of
using general inhibitors of fibril formation to treat a range of protein misfolding diseases. As
such, the identification of the sites responsible for the ability of sHsps to prevent fibril formation
by a range of disease-related target proteins is of great interest and may lead to their development
as therapeutic agents, e.g. via the use of peptide mimics.
5. In vitro and in vivo formation of amyloid fibrils by crystallin proteins
Cataract is a disease of principally crystallin protein aggregation and subsequent precipitation
that occurs over the timeframe of years. Intuitively, one would anticipate that these slow
aggregation conditions would favour the formation of highly ordered aggregates such as amyloid
fibrils. Indeed, as discussed above, a long aggregation timeframe is one criterion that contributes
to the facilitation of fibril formation. However, the protein aggregates that are present in cataract
are generally considered to be amorphous in form with little ordered structure. Accordingly, in
vitro models of target protein aggregation that have investigated the chaperone action of αcrystallin have, in the main, utilized target proteins that aggregate amorphously.
Some in vitro and in vivo work has investigated the possible fibrillar nature of crystallin protein
aggregates in normal and cataractous lenses. Frederikse [146] showed that the amyloidophilic
dyes, Congo red and ThT, bound readily to the crystallin proteins of normal murine lenses in situ.
From this, he concluded that the crystallin proteins in organelle-free lens fibre cells were
arranged in a supramolecular β-sheet structure that had amyloid-like properties. Previous studies
using Raman and infrared spectroscopy had also concluded that β-sheet structure predominates in
the crystallin proteins of the normal lens (references 8 to 15 in [146]). All three crystallins (α,
β and γ) are highly β-sheet in character. The binding of the amyloidophilic dyes to lens proteins
in situ is therefore probably not surprising as they interact with the native state of β-sheet
proteins, including α-crystallin (Carver, Ecroyd et al., unpublished results).
Earlier studies by Frederikse and co-workers had shown that amyloidogenic proteins such as the
Aβ peptide (and its precursor, the amyloid-β precursor protein (APP), and the presenilin enzymes
that cleave APP) and the prion protein are present in low concentrations in the eye lens [146148]. It was hypothesized that species such as Aβ and the prion protein could act as seeds to
facilitate fibril formation by other proteins such as the crystallins. In a similar vein, Goldstein et
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al. [149] showed that inclusions present in equatorial supranuclear cataracts from the lenses of
Alzheimer’s disease patients contained Aβ species which may act to promote crystallin protein
aggregation.
The relationship between the aggregation of amyloid species and R120G αB-crystallin, a
mutation which causes desmin-related myopathy (DRM) and cataract, was examined in
cardiomyocytes by Sanbe et al. [150]. The direct involvement of R120G αB-crystallin in DRM
was demonstrated by halting R120G αB-crystallin expression in transgenic mice which led to the
reduction in amyloid species and improved cardiac function. As a follow-up to these studies,
Sanbe et al. [151] showed that recombinant R120G αB-crystallin at pH 7.5 formed toxic amyloid
oligomers in vitro. The formation of amyloid species was prevented by the presence of two other
sHsps, Hsp25 and Hsp22. In transfected cardiomyocytes, the presence of these two sHsps also
restored ubiquitin/proteasome activity and cell viability [151]. Our work has also shown that
recombinant R120G αB-crystallin forms amyloid fibrils readily [152]. In a recent innovation,
Muchowski et al. [92] have developed a transgenic mouse in which the proteins associated with
Parkinson’s and Huntington’s diseases (α-synuclein and a huntingtin fragment respectively) are
expressed in the lens leading to their aggregation and cataract formation. It is intended to use
these mice as screens to study Parkinson’s and Huntington’s diseases, for example in the
development of therapeutics to inhibit protein aggregation. Interestingly, in mice lacking αBcrystallin the huntingtin fragment exhibited markedly enhanced protein aggregation, implying
that the molecular chaperone action of αB-crystallin was important in suppressing huntingtin
aggregation in vivo.
Our work has shown that each of the crystallin protein classes (α, β and γ) readily forms amyloid
fibrils under mildly denaturing conditions [153]. The fibrils have all the generic structural and
physical characteristics of amyloid fibrils (Fig. 5). A couple of studies have investigated the
fibril-forming propensity of individual γ-crystallin subunits. Quinlan and co-workers [154]
showed that a mutant of murine γB-crystallin with its last (fourth) Greek key motif absent readily
forms amyloid fibrils in vitro. In contrast, the wild type γB-crystallin did not form fibrils. In vivo,
the inherited γB-crystallin mutant caused cataract in mice and produced inclusions in the lens that
had amyloid-like characteristics. Recently, Papankolopoulou et al. [155] showed that wild type
human γD-crystallin, along with its individual N- and C-terminal domains, formed well-defined
amyloid fibrils when incubated at pH 3. Our recent work [152] has investigated in detail, using a
range of biophysical techniques, fibril formation by the individual α-crystallin subunits and
R120G αB-crystallin. In particular, NMR spectroscopy was used to show that the short and
highly mobile C-terminal extension of αB-crystallin [156] maintains its flexibility in the fibrillar
state. Furthermore, NMR measurements determined the diffusion coefficients of the native and
fibrillar forms of αB-crystallin. As expected, this value was significantly larger in the fibrillar
state due to the greater size of the aggregate. Morphologically, the structure of αB-crystallin
fibrils can be varied by altering solution conditions (discussed more in the next section). The
material properties of αB-crystallin fibrils have been examined by measuring their bending
rigidity, from which it was determined that αB-crystallin forms relatively flexible fibrillar species
compared to other systems [157]. The C-terminal extension of αB-crystallin may be responsible
for this flexibility. Recently, Tanaka et al. [139] have examined the fibril-forming propensity and
chaperone activity of peptides from αA-crystallin, specifically those corresponding to the
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putative chaperone-binding regions of the protein previously identified by Sharma et al. [136,
137]. Tanaka et al. [139] found that one of these peptide (70-88) inhibited Aβ fibril formation
but promoted the aggregation of insulin. Interestingly, the 71-88 peptide is itself amyloidogenic
with F71 being a crucial residue for this property. The implication from this result is that the
hydrophobic interactions that facilitate the chaperone activity of sHsps against fibril-forming
target proteins are similar to those that mediate fibril formation in the first place.
Thus, it is apparent for the above discussion that all the crystallins, under appropriate conditions,
will readily form amyloid fibrils. It is possible, therefore, that some of the aggregates present in
cataractous lenses are fibrillar in nature. If present, however, they may be mixed in with
amorphously aggregated crystallin proteins. Interestingly, αA- and αB-crystallin are as
susceptible to fibril formation as the β- and γ-crystallins [152, 153]. Thus, even the molecular
chaperones αA- and αB-crystallin, which are highly stable proteins (like the other crystallins),
are prone to aggregate and form fibrils, despite their role in protein stabilization in the lens.

6. Crystallin proteins as bionanomaterials
The mechanism of amyloid fibril formation has obviously attracted much interest because of the
intimate association of fibrils with diseases of protein misfolding and aggregation. In addition,
the highly structured nature of amyloid fibrils, their ability to self-assemble, their inherent
strength and their possibility to be functionalised have elicited research interest of late in their
potential use as bionanomaterials, for example as drug delivery agents and in the field of
bioelectronics [158]. Nature already produces its own bionanomaterials in the form of functional
amyloid, for example as structural components of lower organisms such as bacteria, fungi and
insects [59]. From a synthetic point of view, bionanomaterials prepared from amyloid fibrils have
advantages over other nanomaterials such as carbon nanotubes in that they are biocompatible and
can be readily functionalized.
Of late, we have been investigating the potential of crystallin proteins as ready sources of
amyloid fibrils for use as bionanomaterials (Garvey et al., submitted for publication). The
advantage of crystallin proteins is their ready availability in significant quantity which is of
particular importance if amyloid fibrils are to be used for commercial purposes. As described
above, individual α- and γ-crystallin subunits readily form fibrils under mildly denaturing
conditions [152, 155] as do the individual α-, β- and γ-crystallin classes [153]. Our recent work
has shown that semi-pure and crude mixtures of the crystallins from bovine, ovine and deer
lenses formed amyloid fibrils under similar conditions employed for the preparation of crystallin
fibrils, i.e. the three individual crystallin classes do not need to be purified individually prior to
fibril preparation. Thus, fibril formation occurred for these mixtures when the α-crystallin
subunits were present which, when acting as molecular chaperones, would have the potential to
prevent fibril formation. The morphology of these fibrils, varying between short and curly and
closed loops to straight, can be altered significantly depending on the solvent conditions.
Likewise, varying solution conditions dramatically alters the morphology of αB-crystallin
amyloid fibrils with acidic pH and dilution leading to the dissociation of the fibrils into shorter
protofibrillar species that include some closed loop structures (Fig. 6).
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In summary, crystallin proteins have great potential as bionanomaterials because of the relative
ease of obtaining significant quantities and the ability to alter their morphology dramatically
depending on the solution conditions for their preparation. Further research in this area will
explore these possibilities and the potential applications of crystallin fibrillar species in the
emerging field of bionanomaterials.
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Table 1: The human crystallin proteins
Crystallin

SwissProt Accession Number

αA-crystallin
αB-crystallin

P02489
P02511

α-crystallins

β-crystallins
βA-crystallins
βA1-crystallin
βA2-crystallin
βA3-crystallin
βA4-crystallin
βB-crystallins
βB1-crystallin
βB2-crystallin
βB3-crystallin

P05813
P53672
P05813
P53673
P53674
P43320
P26998

γ-crystallins
γS-crystallin
γA-crystallin
γB-crystallin
γC-crystallin
γD-crystallin
γE-crystallin*
γF-crystallin*

P22914
P11844
P07316
P07315
P07320
-

* - genes for these proteins are inactive in human due to a nonsense mutation [159].
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Figure Legends.
Figure 1. (A) X-ray crystallographic structures of the γB-crystallin monomer (top) and the
βB2-crystallin dimer (bottom) (from [12]). Both proteins are very similar in secondary
structure in having two domains which are each comprised of four β-strands (shown in blue and
turquoise in γB-crystallin) arranged in two Greek key motifs, i.e. a total of eight β-strands per
domain. The bent nature of the connecting (linker) peptide between the two domains in the γBcrystallin structure ensures that the inter-domain contacts are intramolecular and hence the
protein is a monomer. By contrast, the connecting peptide is straight in βB2-crystallin which
enables intermolecular inter-domain contacts and a dimeric structure results. N and C refer to the
N- and C-termini respectively and P to the crystallographic dyad between the two subunits in the
βB2-crystallin dimer. (B) A schematic diagram of the arrangement of the three structural
regions in a representative sHsp, αB-crystallin. The N-terminal domain comprises residues 1
to 65, the C-terminal (α-crystallin) domain residues 66 to 149 and the C-terminal extension
residues 150 to 175. The last 12 amino acids in αB-crystallin are highly mobile, solvent exposed
and of no ordered structure [2, 3, 11, 20]. (C) Homology modelling of the monomeric subunit
of human αB-crystallin based on the crystal structure of wheat sHsp 16.9 (from [23]). The
figure shows the superposition of the secondary structures of human αB-crystallin (red), wheat
sHsp16.9 (green) and Methanococcus jannasschi sHsp 16.5 (blue). The immunoglobulin-like βsheet fold of the C-terminal (α-crystallin) domain is apparent.
Figure 2. The protein folding/unfolding and off-folding pathways (adapted from [2]). A
native protein (N) unfolds via a variety of intermediate states (I1, I2, I3, …) which can progress to
the unfolded state (U). If the intermediate states linger for long enough, they can enter the offfolding pathways, comprising either the disordered (amorphous) aggregation pathway in which
interaction ultimately produces irreversibly precipitated, amorphously aggregated species or the
amyloid fibril-forming pathway which, via the formation of small, soluble protofibril species,
leads to insoluble, highly ordered cross β-sheet fibril arrays.
Figure 3. Mechanism of sHsp chaperone interaction with amorphously aggregating target
proteins (modified from [2]). sHsps selectively interact with and stabilize slowly aggregating,
intermediately folded target proteins on their amorphous off-folding pathway. The intermediates
(I2) are relatively disordered in structure with only some elements of secondary structure in place.
The dynamic nature of the equilibrium between the monomeric and aggregated I2 species
facilitates interaction with the similarly dynamic sHsp. There is some evidence that the
dissociated, dimeric form of the sHsp is the chaperone-active species which interacts with I2 and
is subsequently sequestered into a high-mass complex containing both proteins. It is possible to
recover natively folded target protein (N) via the action of another chaperone, for example by
Hsp70 action coupled to ATP hydrolysis [6].
Figure 4. The structure of an amyloid fibril. (A) Amyloid fibrils formed by α-lactalbumin as
viewed by transmission electron microscopy. The fibrils are typical of amyloid fibrils formed
from a range of different proteins in being long, unbranched and rope-like. Scale bar is 500 nm.
(B) In the left panel, a magnified electron micrograph view of an amyloid fibril formed by α-
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synuclein. Scale bar is 100 nm. In the middle panel, a schematic view of the arrangement of the
internal protofilaments within the α-synuclein fibril. In the right panel, a schematic view of an
insulin fibril highlighting the substructure of the fibril core, i.e. the typical cross β-sheet array
formed from sheets of β-strands lying perpendicular to the axis of the fibril and the aligning of
these β-sheets into individual filaments (from [52]). (C and D) Structural models of amino acids
that compromise the steric zipper that forms the core of fibrils from (C) the peptide GNNQQNY
[53] and (D) residues 109-122 of the Syrian hamster prion protein [56]. The arrows indicate the
direction of the fibril axis. (E) Mechanisms by which sHsps may act in a chaperone manner
to inhibit amyloid fibril formation by target proteins. The nucleation-dependent mode of
amyloid fibril formation commences with the unfolding of a native protein, forming a pool of
partially folded intermediates, via a process that is reversible. The partially folded intermediates
associate with each other until they reach a critical size/mass at which a stable nucleus is formed.
The formation of this nucleus from the partially folded intermediates is slow and rate-limiting in
the overall process of fibril formation (lag phase). Fibril elongation then proceeds via the addition
of intermediates to the growing nucleus (elongation phase). The mechanism by which sHsps
prevent fibril formation varies depending on the target protein. In a manner analogous to
preventing amorphous target protein aggregation, sHsps recognise and bind to the partially folded
intermediate of target proteins to form a soluble sHsp-target protein complex. This sHsp-target
protein complex may be stable leading to a ‘reservoir of intermediates’ which may be picked-up
and refolded by other chaperone proteins (e.g. Hsp60 and Hsp70). In some cases, sHsps only
form transient complexes with the aggregating protein, releasing it so that it can spontaneously
refold back to its native state via the on-folding pathway. The interaction of sHsps with the
partially folded intermediates also prevents them from being available to facilitate fibril
elongation. In addition, sHsps may act directly with the fibril/nucleus to ‘cap’ it and prevent
further growth.
Figure 5. Transmission electron micrographs of amyloid fibrils formed by α-crystallin
(adapted from Fig. 1 of [153]). Samples of bovine α-crystallin were incubated at 60 °C for 24 h
in varying concentrations of GdnHCl. A, 0.001 M GdnHCl. B, 0.1 M GdnHCl. C, 0.75 M
GdnHCl. D, 1.0 M GdnHCl. Scale bar is 200 nm.
Figure 6. Alteration in morphology of αB-crystallin amyloid fibrils upon varying solvent
conditions (from [152]). Atomic force microscopy images of αB-crystallin fibrils prepared at (a)
pH 7.4 with GdnHCl, then, following a tenfold (b), or 100-fold (c), dilution into a pH 2.0
solution; (d) αB-crystallin fibrils prepared with trifluoroethanol at pH 2.0. Scale bar is 500 nm.

iii

iv

v

vi

vii

viii

